目的 :评价司帕沙星治疗非淋菌性泌尿生殖道炎的有效性。方法 :采用随机对照方法 ,以克拉霉素为对照。共治疗患者 5 0例 ,司帕沙星组 2 6例 ,po ,2 0 0～ 30 0mg ,qd ;克拉霉素组 2 4例 ,po ,2 5 0mg ,q12h。疗程 7～ 14d。结果 :司帕沙星组与克拉霉素组有效率分别为 92 .3%和 91.7% ,痊愈率分别为 84.6 %和 83.3% ,病原菌清除率分别为 92 .3%和 95 .8% ,不良反应发生率分别为 3.85 %和 8.3% ,经统计学处理无显著性差异 (P >0 .0 5 )。结论 :采用司帕沙星治疗非淋菌性泌尿生殖道炎安全有效 Objective: To evaluate the efficacy of sparfloxacin in the treatment of non-gonococcal urogenital tract inflammation. Methods: A randomized controlled trial with clarithromycin as control. A total of 50 patients were treated, sparfloxacin 26 cases, po, 200 ~ 30 0mg, qd; clarithromycin group 24 cases, po, 250mg, q12h. Treatment 7 ~ 14d. Results: The effective rates of sparfloxacin group and clarithromycin group were 92.3% and 91.7%, the cure rates were 84.6% and 83.3% respectively, and the pathogenic bacteria clearance rates were 92.3% and 95.8% Response rates were 3.85% and 8.3%, respectively, and there was no significant difference between the two groups (P> 0.05). Conclusion: The use of sparfloxacin treatment of non-gonococcal genitourinary tract inflammation is safe and effective